[Skip to Content]
[Skip to Content Landing]
October 4, 2006

Drug Safety Monitoring—Reply

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(13):1590. doi:10.1001/jama.296.13.1590-b

In Reply: Dr Ruck and colleagues propose the use of PCCs and their national database, TESS, as a tool for postmarketing drug surveillance. I have long thought that PCCs are an underused resource for the study of dose-related adverse drug reactions.1 After all, what better way to study such reactions than in an overdose setting? However, it is important to place this in proper perspective.